Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 15/20 | 0.50 |
| ▸ | P2RX2 | Q9UBL9 | 15/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19364184 | 0.87 | P2RX3 (0.42) | P2RX3P2RX2HTR2ACYP1A2LMNA | |
| SCHEMBL1494334 | 0.86 | P2RX3 (0.39) | P2RX3P2RX2HTR1AHTR2AHTR2C | |
| SCHEMBL1494241 | 0.85 | HTR2A (0.42) | P2RX3P2RX2HTR1AHTR2AHTR2C | |
| SCHEMBL1494087 | 0.85 | P2RX3 (0.47) | P2RX3P2RX2HTR2A | |
| SCHEMBL14599985 | 0.83 | P2RX3 (0.46) | P2RX3P2RX2HTR2CCYP1A2CYP2D6 | |
| SCHEMBL1493906 | 0.82 | P2RX3 (0.47) | P2RX3P2RX2HTR2AHTR2CTSHR | |
| SCHEMBL20183061 | 0.82 | ALOX15 (0.40) | P2RX3P2RX2CYP3A4LMNA | |
| SCHEMBL4933044 | 0.81 | P2RX3 (0.36) | P2RX3P2RX2HTR1AHTR2AHTR2C | |
| SCHEMBL12205020 | 0.80 | P2RX3 (0.53) | P2RX3P2RX2HTR1AHTR2AHTR2C | |
| SCHEMBL12832328 | 0.78 | P2RX3 (0.34) | P2RX3P2RX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926716-B1 | PROCESS FOR SYNTHESIS OF ARYLOXY DIAMINOPYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-7741484-B2 | Process for synthesis of phenoxy diaminopyrimidine derivatives | ROCHE PALO ALTO LLC (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741484-B2 | Process for synthesis of phenoxy diaminopyrimidine derivatives | ROCHE PALO ALTO LLC (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741484-B2 | Process for synthesis of phenoxy diaminopyrimidine derivatives | ROCHE PALO ALTO LLC (US) | 2010-06-22 | — | — | US | disclosed |
| WO-2008104474-A1 | DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104474-A1 | DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207655-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207655-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207655-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2008-08-28 | — | — | US | disclosed |
| EP-1926716-A1 | PROCESS FOR SYNTHESIS OF ARYLOXY DIAMINOPYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007025898-A1 | PROCESS FOR SYNTHESIS OF ARYLOXY DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049751-A1 | Process for synthesis of phenoxy diaminopyrimidine derivatives | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049751-A1 | Process for synthesis of phenoxy diaminopyrimidine derivatives | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049751-A1 | Process for synthesis of phenoxy diaminopyrimidine derivatives | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207655-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | P2RX3, P2RX2, P2RX6 | P2RX3 1/4885P2RX2 2/4885HTR1A 112/4885 |
| US-20070049751-A1 | Process for synthesis of phenoxy diaminopyrimidine derivatives | TPO, DPYD, DHPS | P2RX3 2368/4885P2RX2 2113/4885HTR1A 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.